Tumor mutational burden as a predictive biomarker for molecularly matched therapy in two independent pan-cancer cohorts

被引：0
|
作者：
Jelas, I [1 ]
de Bortoli, T. [2 ]
Benary, M. [2 ]
Horak, P. [3 ]
Lamping, M. [2 ]
Schaefer, R. [2 ]
Klauschen, F. [2 ]
Tinhofer-Keilholz, I [2 ]
Leyvraz, S. [2 ]
Keller, U. [2 ]
Stenzinger, A.
Froehling, S. [3 ]
Stintzing, S. [1 ,4 ]
Kurzrock, R. [5 ]
Keilholz, U. [2 ]
Rieke, D. [2 ]
机构：
[1] Charite Univ Med Berlin, Klin Hamatol Onkol & Tumorimmunol, Berlin, Germany
[2] Charite Univ Med Berlin, Berlin, Germany
[3] NCT Heidelberg, Heidelberg, Germany
[4] Univ Klinikum Heidelberg, Heidelberg, Germany
[5] Worldwide Innovat Network WIN Assoc WIN Consortiu, Villejuif, France
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2023年 / 46卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
V563
引用
收藏
页码：89 / 90
页数：2
相关论文
共 50 条
  • [31] An integrative evaluation of circadian gene TIMELESS as a pan-cancer immunological and predictive biomarker
    Yang, Yaocheng
    Tang, Xianzhe
    Lin, Zhengjun
    Zheng, Tao
    Zhang, Sheng
    Liu, Tang
    Yang, Xiaolun
    EUROPEAN JOURNAL OF MEDICAL RESEARCH, 2023, 28 (01)
  • [32] Dynamics of predicted tumor neoepitope burden in a pan-cancer solid tumor pediatric cohort
    Macaulay, Charles W.
    Breese, Marcus R.
    Sweet-Cordero, E. Alejandro
    CANCER IMMUNOLOGY RESEARCH, 2023, 11 (12)
  • [33] Systematic pan-cancer analysis identifies ZBTB11 as a potential pan-cancer biomarker and immunotherapy target in multiple tumor types
    Xu, Peiyi
    Zhang, Qiuyan
    Zhai, Jing
    Chen, Pu
    Deng, Xueting
    Miao, Lin
    Zhang, Xiuhua
    DISCOVER ONCOLOGY, 2024, 15 (01)
  • [34] Tumor mutational burden as a tissue-agnostic biomarker for cancer immunotherapy
    Sung, Winnie W. Y.
    Chow, James C. H.
    Cho, William C. S.
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2021, 14 (02) : 141 - 143
  • [35] Tumor mutation burden as a marker for molecularly matched therapy: more evidence needed
    Meng, Xiang-Yu
    Wu, Qiu-Ji
    EPIGENOMICS, 2023, 15 (22) : 1175 - 1178
  • [36] A novel tumor mutational burden estimation model as a predictive and prognostic biomarker in NSCLC patients
    Tian, Yanhua
    Xu, Jiachen
    Chu, Qian
    Duan, Jianchun
    Zhang, Jianjun
    Bai, Hua
    Yang, Zhenlin
    Fang, Wenfeng
    Cai, Liangliang
    Wan, Rui
    Fei, Kailun
    He, Jie
    Gao, Shugeng
    Zhang, Li
    Wang, Zhijie
    Wang, Jie
    BMC MEDICINE, 2020, 18 (01)
  • [37] A novel tumor mutational burden estimation model as a predictive and prognostic biomarker in NSCLC patients
    Yanhua Tian
    Jiachen Xu
    Qian Chu
    Jianchun Duan
    Jianjun Zhang
    Hua Bai
    Zhenlin Yang
    Wenfeng Fang
    Liangliang Cai
    Rui Wan
    Kailun Fei
    Jie He
    Shugeng Gao
    Li Zhang
    Zhijie Wang
    Jie Wang
    BMC Medicine, 18
  • [38] Use of CRTAM expression as a predictive biomarker for immune checkpoint blockade in a pan-cancer cohort
    Miyashita, Hirotaka
    Nishizaki, Daisuke
    Lee, Suzanna
    Nesline, Mary K.
    Conroy, Jeffrey M.
    DePietro, Paul
    Pabla, Sarabjot
    Aoshima, Ken
    Kato, Shumei
    Kurzrock, Razelle
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [39] Increased KRAS G12C Prevalence, High Tumor Mutational Burden, and Specific Mutational Signatures Are Associated With MUTYH Mutations: A Pan-Cancer Analysis
    Disel, Umut
    Sivakumar, Smruthy
    Pham, Tim
    Fleischmann, Zoe
    Anu, R., I
    Sokol, Ethan S.
    Kurzrock, Razelle
    ONCOLOGIST, 2024, 29 (02): : e213 - e223
  • [40] The comprehensive potential of AQP1 as a tumor biomarker: evidence from kidney neoplasm cohorts, cell experiments and pan-cancer analysis
    Liu, Yifan
    Lyu, Donghao
    Yao, Yuntao
    Cui, Jinming
    Liu, Jiangui
    Bai, Zikuan
    Zhao, Zihui
    Li, Yuanan
    Lu, Bingnan
    Dong, Keqin
    Pan, Xiuwu
    HUMAN GENOMICS, 2025, 19 (01)
12345